Recent Advances in Angiogenesis and ... - Bentham Science
Recent Advances in Angiogenesis and ... - Bentham Science
Recent Advances in Angiogenesis and ... - Bentham Science
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
94 <strong>Recent</strong> <strong>Advances</strong> <strong>in</strong> <strong>Angiogenesis</strong> <strong>and</strong> Antiangiogenesis, 2009 Untergasser <strong>and</strong> Gunsilius<br />
rare cell-types that can only be found at lowest<br />
frequencies <strong>in</strong> the circulation of healthy persons <strong>and</strong><br />
tumor patients [21]. They can be identified by their<br />
complex phenotype CD45 low , CD34 + , CD133 + <strong>and</strong><br />
KDR + . These markers are by no way specific for this<br />
cell-type <strong>and</strong> can be also found on subsets of<br />
hematopoietic stem cells [22] or tumor stem cells<br />
[23]. Hitherto, no s<strong>in</strong>gle reliable marker for EPC has<br />
been discovered. Apart from the rare EPC cell-type,<br />
more abundant circulat<strong>in</strong>g endothelial cells (CEC)<br />
have been monitored <strong>in</strong> peripheral blood samples after<br />
damage of the vasculature [24]. CEC are mature<br />
endothelial cells express<strong>in</strong>g CD146 <strong>and</strong> therefore have<br />
a low proliferative potential. CEC are elevated <strong>in</strong><br />
patients with advanced malignancies <strong>and</strong><br />
vasculopathies [25] <strong>and</strong> monitor<strong>in</strong>g of CEC has been<br />
proposed as surrogate marker for therapy-<strong>in</strong>duced<br />
effects [26].<br />
EPC<br />
Transgenic EPC<br />
Transposase<br />
Chromosomal<br />
DNA<br />
Transposon<br />
Transposon<br />
CUT<br />
Based on essential premises for genetic modification<br />
<strong>and</strong> for use <strong>in</strong> cell-based therapies, i.e. (i) a<br />
characterized homogenous cell population, (ii) a high<br />
proliferative capacity <strong>and</strong> (iii) the capacity of term<strong>in</strong>al<br />
endothelial differentiation, BOEC seem the most<br />
appropriate cell-type for cell-based therpies target<strong>in</strong>g<br />
the tumor.<br />
3. GENETIC MODIFICATION OF<br />
ENDOTHELIAL CELLS<br />
Adenovirus<br />
PASTE<br />
permanent expression<br />
Adenoviruses can <strong>in</strong>fect non-divid<strong>in</strong>g cells (see Fig.<br />
2). The adenoviral double str<strong>and</strong>ed DNA is not<br />
<strong>in</strong>corporated <strong>in</strong>to the host-genome <strong>and</strong> rema<strong>in</strong>s<br />
episomal as separate extra-chromosomal element <strong>in</strong> the<br />
Adenoviral transfection<br />
EPC transgenic EPC<br />
Viral<br />
DNA<br />
Plasmid<br />
GENE<br />
GENE<br />
GENE<br />
GENE<br />
GENE<br />
RECOMBINATION<br />
transient expression<br />
transgenic EPC<br />
Fig. (2). Viral <strong>and</strong> non-viral systems for the genetic manipulation of endothelial cells. Recomb<strong>in</strong>ant adenoviruses can<br />
be generated by homologue recomb<strong>in</strong>ation of the plasmid conta<strong>in</strong><strong>in</strong>g the gene of <strong>in</strong>terest with the adenoviral DNA.<br />
These viruses are used to <strong>in</strong>fect endothelial cells, that <strong>in</strong> turn transiently express the transgene GFP. The Sleep<strong>in</strong>g<br />
Beauty (SB) transposon carry<strong>in</strong>g the gene of <strong>in</strong>terest is "cut" out of the plasmid vector by the eng<strong>in</strong>e of this mach<strong>in</strong>e<br />
(the transposase) <strong>and</strong> then "pasted" directly <strong>in</strong>to the chromosome of endothelial cells, that <strong>in</strong> turn permanently express<br />
GFP.<br />
GFP<br />
GFP